Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Viridian Therapeutics, Inc. (MGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/17/2023 8-K Quarterly results
07/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease",
"Viridian Therapeutics, Inc. Data Presentation, dated July 2023"
06/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan",
"Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan"
05/09/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/08/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates"
02/06/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease",
"Viridian Therapeutics, Inc. Topline Data Presentation, dated January 2023"
08/19/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/05/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, among Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to time party thereto and Hercules Capital, Inc., as Agent",
"Loan and Security Agreement, among Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to time party thereto and Hercules Capital, Inc., as Agent"
03/10/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"VIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
11/08/2021 8-K Other Events  Interactive Data
11/04/2021 8-K Quarterly results
Docs: "VIRIDIAN THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
09/23/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
07/26/2021 8-K Appointed CFO
Docs: "Kristian Humer Employment Agreement",
"VIRIDIAN THERAPEUTICS APPOINTS KRISTIAN HUMER AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER BOULDER, Colo., July 26, 2021 — Viridian Therapeutics, Inc. , a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. “Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives we've already assembled in recent months, as we advance our pipeline of investigational therapies to address serious diseases with significant unmet medical needs,” commented Jonathan Violin, Ph.D., President and Chief Executive Officer of..."
07/15/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"VIRIDIAN THERAPEUTICS APPOINTS JENNIFER MOSES, CPA TO THE BOARD OF DIRECTORS AND AS CHAIR OF THE AUDIT COMMITTEE BOULDER, Colo., July 15, 2021 — Viridian Therapeutics, Inc. , a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the appointment of Jennifer Moses, CPA to the Company's Board of Directors and as Chair of the Audit Committee. “We are excited to welcome Jennifer to our Board of Directors and as Chair of the Audit Committee. She provides strong financial and strategic experience as a successful leader in the biotechnology industry. Her addition to the Board and as Chair of the Audit Committee will be of great benefit to Viridian as we rapidly advance the clinical development of VRDN..."
06/04/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
01/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT OF MIRAGEN THERAPEUTICS, INC.",
"RESTATED CERTIFICATE OF INCORPORATION",
"AMENDED AND RESTATED BYLAWS OF",
"MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT",
"SEPARATION AND RELEASE AGREEMENT"
01/04/2021 8-K Quarterly results
12/17/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor using Xencor’s Xtend™ half-life extension technology"
12/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "License Agreement, by and between the Company and ImmunoGen, dated as of October 12, 2020*",
"License Agreement, by and between the Company and ImmunoGen, dated as of October 12, 2020*"
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/13/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT OF MIRAGEN THERAPEUTICS, INC."
11/10/2020 8-K Quarterly results
Docs: "MIRAGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy